## Investigation Priority in Osteosarcoma Staging ### Why CT Chest is Most Critical **Key Point:** Pulmonary metastases are present in 15–20% of patients at initial diagnosis and are the most common site of distant spread. Detecting metastases changes the treatment plan and prognosis dramatically. **High-Yield:** The presence of pulmonary metastases at diagnosis: - Downgrades the patient from localized to metastatic disease - Requires modified chemotherapy protocols - Necessitates pulmonary resection planning (if feasible) - Significantly worsens prognosis (5-year survival drops from ~70% to ~20%) ### Staging Workup Hierarchy | Investigation | Purpose | Timing | Operability Impact | |---|---|---|---| | **CT chest ± abdomen** | Detect pulmonary/visceral metastases | **Before surgery** | **CRITICAL** — metastases = palliative intent | | **MRI local** | Define soft tissue/marrow extent, surgical margins | Before surgery | Important for surgical planning | | **Pulmonary function tests** | Assess reserve if pulmonary resection planned | Before surgery | Important if mets present | | **Serum ALP, LDH** | Prognostic markers, monitor chemotherapy response | Baseline + ongoing | Prognostic, not staging | | **Bone scan / skeletal survey** | Detect skeletal metastases | Rarely needed now (PET-CT preferred) | Low yield in osteosarcoma | ### Clinical Algorithm ```mermaid flowchart TD A[Osteosarcoma diagnosed on biopsy]:::outcome --> B[CT chest + abdomen]:::action B --> C{Pulmonary metastases?}:::decision C -->|Yes| D[Metastatic disease<br/>Modified chemo + consider<br/>pulmonary resection]:::urgent C -->|No| E[Localized disease]:::outcome E --> F[MRI for surgical<br/>planning]:::action F --> G[Neoadjuvant chemo<br/>+ wide resection]:::action G --> H[Assess chemotherapy<br/>response]:::action ``` ### Why Other Options Are Secondary **Bone scan / skeletal survey:** Osteosarcoma rarely metastasizes to bone; these investigations have low yield and have been largely replaced by PET-CT in modern practice. **MRI of affected limb:** Essential for surgical planning (soft tissue extension, marrow involvement, neurovascular proximity) but does NOT change operability decision if metastases are present. **Serum tumor markers (ALP, LDH):** Prognostic markers and used to monitor chemotherapy response, but NOT staging investigations. Elevated levels do not change the treatment plan in the way that metastases do. **Clinical Pearl:** The surgical approach (limb-salvage vs. amputation) is determined by local extent (MRI) and vascular involvement, but the decision to pursue curative intent surgery is determined by the absence of distant metastases (CT chest). **Mnemonic — OSTEOSARCOMA STAGING:** **CHEST FIRST** (CT chest before any other imaging to rule out pulmonary metastases, which change prognosis and treatment intent) 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.